Evaluating the Nervous System in ALS Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to assess the progression of autonomic and sensory nervous system involvement in patients with amyotrophic lateral sclerosis (ALS) within 18 months of motor symptom onset. It employs a multimodal approach, including skin biopsies and various clinical assessments, to explore the relationship between autonomic dysfunction and overall disease progression. The study seeks to identify biomarkers in the skin that could serve as reliable measures for tracking disease progression and response to future treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ALS patients will be recruited within 18 months from the motor symptoms onset

Exclusion Criteria:

* glucose intolerance or conditions potentially affecting the peripheral nervous system

Where it's running

• ICS Maugeri - IRCCS of Telese Terme
  Telese Terme, Benevento, Italy Recruiting
• Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II
  Naples, Italy Recruiting

Study contacts

• Principal investigator: Maria Nolano, MD, PhD — Istituti Clinici Scientifici Maugeri SpA
• Study coordinator: Maria Nolano, MD, PhD
• Email: maria.nolano@icsmaugeri.it
• Phone: +390824909257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Implanted Brain-Computer Interface to Help People with Severe Arm Impairment

  We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.

  Recruiting Neuralink Corp · Miami, Florida · NCT07929792

• Brain-computer interface chat tool for people with ALS

  This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.

  Recruiting Cognixion · Santa Barbara, California · NCT07871071

• BIIB147 safety and how it behaves in adults with ALS

  This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.

  Recruiting at 2 sites Phase 1/2 Biogen · St Louis, Missouri and 1 other locations · NCT07855211

• Aims to restore UNC13A function in people with ALS

  This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.

  Recruiting at 6 sites Phase 1/2 Trace Neuroscience, Inc. · Lübeck, Schleswig-Holstein and 5 other locations · NCT07674667

• LTX-002 in adults with ALS

  A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.

  Recruiting at 4 sites Phase 1/2 Leal Therapeutics, Inc · Lübeck and 4 other locations · NCT07660614

• Repeated ultrasound-assisted blood-brain barrier opening in ALS

  This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.

  Recruiting Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris · NCT07571486

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.